Pharmacy Section II

TOC required

201.100 Arkansas Medicaid Participation Requirements for Prescribing Pharmacists and for Pharmacies Administering Vaccines

6-1-22

The Arkansas Medicaid Program will allow pharmacists to enroll individually as atypical providers to prescribe and administer specified drugs and test and screen for certain health conditions, per current allowable protocols. Pharmacists are not billing providers, but they may be rendering providers on medical claims. Pharmacists will be allowed as prescribing providers on pharmacy claims for drugs identified in current protocol.

The Arkansas Medicaid Program will reimburse pharmacies the cost and administration fee for selected vaccines and immunizations for Medicaid clients three (3) years of age and older under current protocol and written consent of the parent or legal guardian of the minor. Consent must be obtained before the administration of the vaccine or immunization. Written protocol and consent must be retained and is subject to reporting requirements. For a complete list of covered vaccines and CMS-1500 billing instructions, please refer to the CMS-1500 Claim Form Billing Instructions.

The Arkansas Medicaid Program will reimburse pharmacies the administration fee for selected vaccines that are obtained through the Vaccine for Children Program (VFC) or ARKids-B SCHIP Vaccine Program. Please refer to section 292.950 of the Physician manual for VFC vaccines billing procedures and section 262.430 for ARKids-B SCHIP vaccine. All Arkansas State Board of Pharmacy laws and regulations will apply.

To be eligible for participation, the pharmacy must meet the following criteria, in addition to those specified in Section 201.000:

- A. Complete Section III, Item 22, of the enrollment application (<u>view or print Provider Enrollment application material</u>) if the pharmacist is certified to administer the influenza virus and pneumococcal polysaccharide vaccines; and
- B. Pharmacies must be enrolled in the Title XVIII (Medicare) Program to administer the vaccines.

Refer to Section 210.100 for scope of coverage; Section 213.000 for benefit limits.

STATE PLAN UNDER TITLE XIX OF THE SOCIAL SECURITY ACT MEDICAL ASSISTANCE PROGRAM STATE ARKANSAS

ATTACHMENT 3.1-A Page 3b

AMOUNT, DURATION AND SCOPE OF SERVICES PROVIDED

Revised:

June 1, 2022

CATEGORICALLY NEEDY

- 6. Medical Care and any other type of remedial care recognized under State law, furnished by licensed practitioners within the scope of their practice as defined by State law. (Continued)
- 6.d. Other Practitioners' Services (Continued)
 - (5) Psychologists

Refer to Attachment 3.1-A, Item 4.b. (13).

(6) Obstetric - Gynecologic and **Gerontological** Nurse Practitioner

Refer to Attachment 3.1-A, Item 24 for coverage limitations.

(7) Pharmacists

TN: 22-0001 Approved:05/03/2022 Effective:06/01/2022

Supersedes TN:AR-01-25

STATE PLAN UNDER TITLE XIX OF THE SOCIAL SECURITY ACT MEDICAL ASSISTANCE PROGRAM STATE <u>ARKANSAS</u>

ATTACHMENT 3.1-B Page 3d

AMOUNT, DURATION, AND SCOPE OF SERVICES PROVIDED

Revised:

June 1, 2022

MEDICALLY NEEDY

- 6. Medical care and any other type of remedial care recognized under State law, furnished by licensed practitioners within the scope of their practice as defined by State law. (Continued)
- 6.d. Other Practitioners' Services (Continued)
 - (5) Psychologists

Refer to Attachment 3.1-A, Item 4.b.(13).

(6) Obstetric - Gynecologic and **Gerontological** Nurse Practitioner

Refer to Attachment 3.1-B, Item 21 for coverage limitations.

(7) Pharmacists

TN: 22-0001 Approved:05/03/2022 Effective:06/01/2022

Supersedes TN: AR-01-25

FINANCIAL IMPACT STATEMENT

PLEASE ANSWER ALL QUESTIONS COMPLETELY

DE	PAR	TMENT	Department	<u>of Human Serv</u>	vices					
DI	VISIO	ON	Division of l	Medical Servic	es					
PE	RSO	N COMPL	ETING THIS	S STATEMEN	NT <u>Jason Callan</u>					
TE	LEPI	HONE 501	-320-6540	FAX	EMAIL: Jason	.Callan@dhs.	arkansas.gov			
To Sta	comj ateme	ply with Ar nt and file	k. Code Ann. two copies wi	§ 25-15-204(e) th the question), please complete the follow naire and proposed rules.	ing Financial	Impact			
SHORT TITLE OF THIS RULE				Pharmacy Manual Update 3-21 and SPA 2022-0001						
1.	Doe	s this propo	osed, amended	l, or repealed ru	ale have a financial impact?	Yes 🔀	No 🗌			
2.					n available concerning the	Yes 🔀	No 🗌			
3.	In consideration of the alternatives to this rule, was by the agency to be the least costly rule considered					Yes 🔀	No 🗌			
	If an agency is proposing a more costly rule, please state the following:									
	(a) How the additional benefits of the more costly rule justify its additional cost;									
	(b) The reason for adoption of the more costly rule;									
	(c)		the more costl explain; and;	pest reasonably obtainable scientific, technical, more and information available concerning the of, and alternatives to the rule? Atternatives to this rule, was this rule determined east costly rule considered? Atternatives to this rule, was this rule determined east costly rule, please state the following: A more costly rule, please state the following: A benefits of the more costly rule justify its additional cost; A ption of the more costly rule; Costly rule is based on the interests of public health, safety, or welfare, and if and; A is within the scope of the agency's statutory authority; and if so, please is to implement a federal rule or regulation, please state the following: implement the federal rule or regulation?						
	(d)	(d) Whether the reason is within the scope of the agency's statutory authority; and if so, please explain.								
4.	If the purpose of this rule is to implement a federal rule or regulation, please state the following: (a) What is the cost to implement the federal rule or regulation?									
<u>Cı</u>	ırren	t Fiscal Ye	<u>ar</u>		Next Fiscal Year					
General Revenue \$ Federal Funds \$ Cash Funds Special Revenue			General Revenue Federal Funds Cash Funds Special Revenue	\$ \$						

Other (Identify)		Other (Identify)					
Total \$		Total §	S				
(b) What is the	additional cost of the state rule?						
Current Fiscal Year		Next Fiscal Year	Next Fiscal Year				
General Revenue Federal Funds Cash Funds Special Revenue Other (Identify)	\$2,602 \$6,565	Cash Funds Special Revenue	\$31,218 \$78,782				
Total	\$9,167		\$110,000				
proposed, amende they are affected. Current Fiscal Year	d, or repealed rule? Identify the	entity(ies) subject to the Next Fiscal Year \$					
Current Fiscal Year \$ 2,602	<u>-</u>	Next Fiscal Year \$ 31,218					
or obligation of at	e agency's answers to Questions a least one hundred thousand dolla	rs (\$100,000) per year to	a private individual,				
private entity, private business, state government, county government, municipal government, or to two (2) or more of those entities combined?							
Yes No No							
If YES, the agency is required by Ark. Code Ann. § 25-15-204(e)(4) to file written findings at the time of filing the financial impact statement. The written findings shall be filed simultaneously with the financial impact statement and shall include, without limitation, the following:							
(1) a statement of the rule's basis and purpose;							
(2) the problem the agency seeks to address with the proposed rule, including a statement of whether a rule is required by statute;							
 (3) a description of the factual evidence that: (a) justifies the agency's need for the proposed rule; and (b) describes how the benefits of the rule meet the relevant statutory objectives and justify the rule's costs; 							

- (4) a list of less costly alternatives to the proposed rule and the reasons why the alternatives do not adequately address the problem to be solved by the proposed rule;
- (5) a list of alternatives to the proposed rule that were suggested as a result of public comment and the reasons why the alternatives do not adequately address the problem to be solved by the proposed rule;
- (6) a statement of whether existing rules have created or contributed to the problem the agency seeks to address with the proposed rule and, if existing rules have created or contributed to the problem, an explanation of why amendment or repeal of the rule creating or contributing to the problem is not a sufficient response; and
- (7) an agency plan for review of the rule no less than every ten (10) years to determine whether, based upon the evidence, there remains a need for the rule including, without limitation, whether:
 - (a) the rule is achieving the statutory objectives;
 - (b) the benefits of the rule continue to justify its costs; and
 - (c) the rule can be amended or repealed to reduce costs while continuing to achieve the statutory objectives.